Loading...
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi, K Massard, C Bono, P Jones, R Kataja, V James, N Garcia, J Protheroe, A Tammela, T Elliott, Tony
Fizazi, K
Massard, C
Bono, P
Jones, R
Kataja, V
James, N
Garcia, J
Protheroe, A
Tammela, T
Elliott, Tony
Citations
Altmetric:
Abstract
ODM-201 is a novel androgen receptor (AR) inhibitor designed to block the growth of prostate cancer cells through high-affinity binding to the AR and inhibition of AR nuclear translocation. This trial assessed ODM-201's safety, pharmacokinetics, and activity in men with metastatic castration-resistant prostate cancer.
Description
Date
2014-06-25
Publisher
Collections
Keywords
Type
Article
Citation
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. 2014: Lancet Oncol.